Business · 19/07/2010Updated: 10/17/2026 · 1 min read

National Institutes of Health to Grant Exclusive License for Cancer Treatment Therapeutics to MedImmune, LLC

Summary

The National Institutes of Health is considering granting an exclusive patent license to MedImmune, LLC to practice inventions related to cancer treatment, including immunotoxins and mutated anti-CD22 antibodies, as outlined in several US patent applications.

Original source language: Federal Register — Health and Human ServicesOpen original release →

Add your company to Business Communicator

We monitor business sources and connect attention with companies, profiles and services available in Business Communicator.

Create a free company profile Explore businesses on Business Maps →

Create a free company profile →

Explore insights

Business insights →

Healthcare Business News Global Markets News Trade Regulation News Business Technology News Fintech for Business: Payments & Banking News Supply Chain News

Related business signals

Business · 9/15/2026

National Cancer Institute Considers Exclusive Patent License for Engineered Cell Therapies for HPV 16 E6-Expressing Cancers

The National Cancer Institute, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive patent license to MedGene Therapeutics, Inc., a Maryland-based company, to develop and commercialize engineered cell therapies for treating cancers caused by the HPV 16 E6 gene.

Read summary →

Business · 9/16/2026

NIH Proposed Collection; 60-Day Comment Request; NIH Intramural Reporting of Research Misconduct (IRRM) Web Form

The National Institutes of Health (NIH) is proposing a web-based reporting form to help the Agency Intramural Research Integrity Officer (AIRIO) assess concerns and determine appropriate next steps in evaluating allegations of research misconduct.

Read summary →

Business · 9/14/2026

NIH Proposes Enhanced Biosafety Policy for Biohazard Research

The National Institutes of Health is seeking public input on a new, comprehensive biosafety policy aimed at strengthening oversight and keeping pace with evolving biohazard risks, with the goal of ensuring gold-standard science under gold-standard biosafety conditions.

Read summary →

Business · 9/14/2026

NIH Requests Public Comment on Proposed Collection of Data for NIH Certificates of Confidentiality

The National Institutes of Health (NIH) is seeking public comment on a proposed data collection project, as required by the Paperwork Reduction Act of 1995, before submitting it to the Office of Management and Budget (OMB) for review and approval.

Read summary →

Business · 9/16/2026

Government-Owned Inventions; Availability for Licensing

The National Institute of Allergy and Infectious Diseases (NIAID) is giving notice of a government-owned invention available for licensing to achieve commercialization of federally funded research results.

Read summary →

Business · 9/15/2026

National Cancer Institute Announces Closed Meeting

The National Cancer Institute has issued a notice regarding a closed meeting, which is not open to the public.

Read summary →